Revista alergia Mexico最新文献

{"title":"TempTest®: un instrumento de precisión en las urticarias físicas.","authors":"Solange Rodrigues-Valle,&nbsp;Guilherme Azizi,&nbsp;Sérgio Duarte-Dortas","doi":"10.29262/ram.v68i1.827","DOIUrl":"https://doi.org/10.29262/ram.v68i1.827","url":null,"abstract":"<p><strong>Background: </strong>TempTest® is a new method based on the Peltier effect, which is validated for the diagnosis of patients with cold urticaria or heat urticaria, and it is able to measure the temperature variations and activity of these pathologies.</p><p><strong>Objective: </strong>To analyze the results of provocation tests by using this new method in patients with UFr and UCal, who were followed in a center of reference and excellence for urticaria (GA2LEN UCARE) in Rio de Janeiro.</p><p><strong>Methods: </strong>The medical records of 12 patients who had a history of UFr or UCal and were tested with TempTest® during December 2017 and February 2020 were analyzed. For temperature provocation tests, the patients were requested to place their forearm on the TempTest® thermal element for five minutes. A positive response was defined by the appearance of a 2-mm-papular lesion 10 minutes after the provocation test was started, as recommended.</p><p><strong>Results: </strong>10 of the patients were women and 2 of them were men, from 13 to 77 years of age (mean = 50.2 years). Among the twelve patients, three of them had heat urticaria and nine of them had cold urticaria. The patients who were diagnosed with heat urticaria tested positive for The patients with cold urticarial tested positive for temperatures of 27 °C or lower.</p><p><strong>Conclusions: </strong>TempTest® is a reliable instrument to accurately diagnose and monitor diseases related to temperature variations, which is a factor that should be determined whenever possible since it can help patients prevent situations of exposure and danger.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 1","pages":"2-6"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39250124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Contact dermatitis caused by diagnostic devices and surgical orthopedic treatment].","authors":"Lucía Moreno-Lozano,&nbsp;Oscar González-Jiménez,&nbsp;Rosa María García-Rodríguez,&nbsp;Alba María Extremera-Ortega,&nbsp;Juana Bautista Joyanes-Romo,&nbsp;Alejandro Gratacós-Gómez,&nbsp;Elisa Gómez-Torrijos","doi":"10.29262/ram.v68i1.830","DOIUrl":"https://doi.org/10.29262/ram.v68i1.830","url":null,"abstract":"<p><strong>Background: </strong>Acrylates are plastic materials that are formed by the polymerization of monomers that are derived from acrylic or methacrylic acid; they have a wide range of applications, and they are increasingly used in medicine.</p><p><strong>Case report: </strong>We are reporting two clinical cases of contact dermatitis in the hospital environment; the first one is about a nurse (occupational exposure) and, the second one, about a patient who experienced contact dermatitis after a diagnostic procedure was performed.</p><p><strong>Conclusion: </strong>New sources of acrylates are identified every year due to the multiple uses of these synthetic resins; these materials are included in medical devices, both for orthopedic diagnosis or follow-up (telemetry, electrodes of electroencephalographs) and treatment (bone cement), as well as for surgery.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 1","pages":"76-79"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39248055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Hypersensitivity to β-lactam antibiotics: algorithms of management and desensitization as a vital therapeutic alternative].","authors":"Ricardo Cardona,&nbsp;Luis Santamaría,&nbsp;Liliana Guevara-Saldaña,&nbsp;Ana Calle","doi":"10.29262/ram.v68i1.892","DOIUrl":"https://doi.org/10.29262/ram.v68i1.892","url":null,"abstract":"<p><p>Hypersensitivity reactions can be complex and life-threatening to patients, especially when drugs such as β-lactam antibiotics are involved. To this day, there are diagnostic algorithms and mobile applications that improve the clinical approach, as well as laboratory tests and more specialized procedures, such as skin tests and controlled exposure tests; which are useful for identifying the drug involved and for selecting safe and effective therapeutic alternatives. For several years, the desensitization procedure has been positioned as a vital tool for clinical allergists and for their patients, and it is key to improving clinical outcomes such as survival and quality of life.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 1","pages":"35-47"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39250126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Rituximab as treatment for refractory pemphigus in Mexican patients].","authors":"Samantha Cruz-Meza,&nbsp;León Felipe Ruiz-Arriaga,&nbsp;María Teresa Barrón-Tapia,&nbsp;Lorena Estrada-Aguilar","doi":"10.29262/ram.v68i1.826","DOIUrl":"https://doi.org/10.29262/ram.v68i1.826","url":null,"abstract":"<p><strong>Background: </strong>Pemphigus (Pm) is a chronic and recalcitrant autoimmune disease that affects the skin and mucous membranes. The first line of treatment are systemic corticosteroids; however, there are patients who are refractory to them, as well as to other immunosuppressants. Rituximab has been used as a successful alternative since 2000 with good results but without information on its behavior in the Mexican population.</p><p><strong>Objective: </strong>To assess the clinical response to treatment with rituximab in Mexican patients with pemphigus.</p><p><strong>Methods: </strong>This was a cross-sectional, retrospective study in a tertiary hospital, which included patients with moderate-severe pemphigus who had been treated with rituximab from 2007 to 2020.</p><p><strong>Results: </strong>Six medical records of patients diagnosed with pemphigus were obtained; four of them with Pm vulgaris, and two of them with pemphigus foliaceus; all patients had received systemic immunosuppressive therapy prior to rituximab. All six patients went into remission of the disease in an average of 12.5 weeks.</p><p><strong>Conclusion: </strong>The use of rituximab for the treatment of patients with moderate-severe Pm who were refractory to immunosuppressive therapy proved to be very useful, and control of the disease was achieved in the medium term, without severe or idiosyncratic adverse effects in the analyzed Mexican population.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 1","pages":"7-11"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39250127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[MIA 2021, Comprehensive Asthma Management. Guidelines for Mexico].","authors":"Désireeé Larenas-Linnemann,&nbsp;Jorge Salas-Hernández,&nbsp;Blanca E Del Río-Navarro,&nbsp;Jorge A Luna-Pech,&nbsp;Elsy Maureen Navarrete-Rodríguez,&nbsp;Laura Gochicoa,&nbsp;María Carmen Cano-Salas,&nbsp;Ulises Noel García-Ramírez,&nbsp;Carmen López-Estrada,&nbsp;José Antonio Ortega-Martell,&nbsp;Ambrosio Aguilar-Aranda,&nbsp;Sergio Caretta-Barradas,&nbsp;Martín Bedolla-Barajas,&nbsp;Robert Camargo,&nbsp;Francisco J Cuevas-Schacht,&nbsp;Margarita Fernández-Vega,&nbsp;Carlos García-Bolaños,&nbsp;Claudia Garrido-Galindo,&nbsp;Alejandro Jiménez-Chobillón,&nbsp;Carlos Juárez-Ortiz,&nbsp;María Carmen Larios-García,&nbsp;Héctor León-Molina,&nbsp;Alejandra Macías-Weinmann,&nbsp;Eric Martínez-Infante,&nbsp;Norma E Martínez-Jiménez,&nbsp;Rocío Esmeralda Mateos-Martínez,&nbsp;Jaime Mellado-Ábrego,&nbsp;Víctor Manuel Mendoza-Romero,&nbsp;Carol Vivian Moncayo-Coello,&nbsp;Sergio Monraz-Pérez,&nbsp;Gabriel Montes,&nbsp;Francisco Ignacio Ignacio Ortiz-Aldana,&nbsp;Carlos Lenin Pliego-Reyes,&nbsp;Adela Reyes,&nbsp;Irasema Rodríguez-Godínez,&nbsp;Héctor Hernán Ruiz-Gutiérrez,&nbsp;Andrés Sánchez-González,&nbsp;César F Segovia-Montero,&nbsp;Saraí Carmen Toral-Freyre,&nbsp;Jorge Vázquez-García","doi":"10.29262/ram.v68i5.880","DOIUrl":"https://doi.org/10.29262/ram.v68i5.880","url":null,"abstract":"<p><strong>Background: </strong>Asthma continues to be one of the most frequent chronic respiratory diseases in our country. New methods for diagnosis and treatment have been described; accordingly, the international guidelines were renewed.</p><p><strong>Objective: </strong>To create a national platform for the development of updated guidelines, solidly based on evidence: Comprehensive Asthma Management (Spanish acronym: MIA).</p><p><strong>Methods: </strong>MIA uses the ADAPTE method. The MIA development group consists of experts in pulmonology-allergology-methodology and representatives of 13 institutions and societies of specialties that manage asthma. The international reference guidelines (selected with AGREE-II): GINA 2020, GEMA 5.0, BTS/SIGN 2019 and ATS/ERS consensus document 2014-2019 on severe asthma. MIA covers suspected asthma, diagnosis, treatment, and special groups. Key clinical questions were formulated on treatment steps 1-3, biomarkers and severe asthma.</p><p><strong>Results: </strong>Based on evidence, safety, cost and local reality, the core group developed responses. Through a Delphi process the broad MIA development group suggested adjustments until consensus was reached.</p><p><strong>Conclusion: </strong>A document was generated with multiple figures and algorithms, solidly based on evidence about asthma management, adjusted for Mexico with a broad base among different societies that participated in its development. It does not include guidelines for acute asthma.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 Suppl 1 ","pages":"s1-s122"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39224402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Warfarin desensitization. A case report].","authors":"Fernando Steven Fuentes-Abreu,&nbsp;Juan Camilo Ardila-Herrera,&nbsp;María Raigosa","doi":"10.29262/ram.v68i1.855","DOIUrl":"https://doi.org/10.29262/ram.v68i1.855","url":null,"abstract":"<p><strong>Background: </strong>Warfarin is an oral anticoagulant which is widely used in the prevention and treatment of thromboembolic events, to which multiple adverse effects are attributed; nevertheless, descriptions of hypersensitivity reactions to this medication are rare.</p><p><strong>Case report: </strong>A 59-year-old patient with a history of mesenteric thrombosis, who had previously received long-term treatment with warfarin. Upon discontinuation of the medication, the patient experienced a recurrence of thrombosis at a hepatosplenic level, with a subsequent hypersensitivity reaction upon administration of the coumarin. It was decided that treatment with warfarin should be continued as it was considered the best therapeutic option, which is why a rapid desensitization protocol was carried out.</p><p><strong>Conclusion: </strong>Hypersensitivity reactions to warfarin are rare; we propose the option of a desensitization protocol for patients who require this medication as long as the clinical benefit is considered greater than the reaction.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 1","pages":"80-83"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39248060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Risk, association, and impact measures in clinical research studies. How to interpret them for their application in medical care].","authors":"Mario Enrique Rendón-Macías,&nbsp;Heladia García,&nbsp;Miguel Ángel Villasís-Keever","doi":"10.29262/ram.v68i1.886","DOIUrl":"https://doi.org/10.29262/ram.v68i1.886","url":null,"abstract":"<p><p>The practice of evidence-based medicine includes the critical analysis of clinical research studies, and, within it, the interpretation of the results reported. In addition, to statistical data, there are estimators that can help clinicians transfer research findings to routine clinical practice. These estimators are measures of risk, association, and impact. Risk measures report current uncertainty or probability (prevalence of a disease, sensitivity, specificity) or for future events (cumulative incidence, incidence density). Measures of association are related to the identification of the risk in order to determine whether certain factors increase or decrease the probability of development of a disease (relative risk, odds ratio, hazard ratio). While measures of impact allow, among other things, to estimate the effect of a treatment (relative risk reduction, absolute risk reduction, number needed to treat). In this review, each of these estimators is described, defined, and presented with examples.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 1","pages":"65-75"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39248056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Obesity in adulthood is associated with the severity of asthma, but not with asthma control].","authors":"Martín Bedolla-Barajas,&nbsp;Jaime Morales-Romero,&nbsp;Juan Carlos López-Hernández,&nbsp;Tonatiuh Ramses Bedolla-Pulido,&nbsp;Lourdes Fabiola García-Padilla,&nbsp;Martín Robles-Figueroa,&nbsp;Miriam Montzerrat Flores-Razo","doi":"10.29262/ram.v68i1.756","DOIUrl":"https://doi.org/10.29262/ram.v68i1.756","url":null,"abstract":"<p><strong>Background: </strong>The impact of obesity on the severity of asthma continues to be a cause of controversy.</p><p><strong>Objective: </strong>To compare the severity of asthma and asthma control in obese patients with non-obese patients.</p><p><strong>Methods: </strong>A cross-sectional study which included 188 patients with asthma, of ≥ 18 years of age, who were selected consecutively. The patients were categorized and compared based on the presence or absence of obesity. In order to establish an association between variables, logistic regression analyses were performed.</p><p><strong>Results: </strong>In total, 111/188 of the patients had obesity; these patients were older than those without obesity (35.9 ± 15.3 years vs. 44.4 ± 13.8 years, p <0.001). No significant difference was observed in the groups regarding sex, total IgE serum concentration, peripheral blood eosinophil count, personal history of atopic diseases, frequency of allergic sensitization, hospitalization for asthma, and asthma control. Overall, obesity was significantly associated with moderate-severe asthma (OR = 1.82, p = 0.047), but not with asthma control (p = 0.094).</p><p><strong>Conclusions: </strong>Our results suggest that patients with asthma and obesity are older and that their pulmonary function is worse, which is reflected in a greater level of severity of asthma.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 1","pages":"26-34"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39248059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical characteristics of a population with atopic dermatitis in a tertiary center].","authors":"Catalina Rincón-Pérez,&nbsp;Carmen Gabriela Torres-Alarcón,&nbsp;Saraid Cerda,&nbsp;Juan Gabriel Maldonado-Hernández,&nbsp;Patricia Marín-Ambrocio,&nbsp;Rocío Tovar-Franco","doi":"10.29262/ram.v68i1.843","DOIUrl":"https://doi.org/10.29262/ram.v68i1.843","url":null,"abstract":"BACKGROUND\u0000Information about the clinical and epidemiological characteristics of atopic dermatitis (AD) is essential to generate knowledge of the disease and its socioeconomic impact.\u0000\u0000\u0000OBJECTIVE\u0000To describe the clinical characteristics of the patients of an atopic dermatitis clinic.\u0000\u0000\u0000METHODS\u0000An observational, retrospective, and cross-sectional study. Demographic data, severity of the AD (according to the Eczema Area Severity Index), clinical phenotype, total serum IgE, the presence of allergic and non-allergic comorbidities, as well as of anxiety and depression, were recorded by means of targeted questionnaire and Hamilton Scale. Descriptive and inferential statistics were obtained, considering a statistical significance associated with a value of p <0.05.\u0000\u0000\u0000RESULTS\u0000187 patients were included; the median age was 12 years with a range of 1-87 years. Differences were found regarding sex and severity (p < 0.05). Mild forms of AD were presented in 57.8% of the patients, moderate forms in 20.9%, and severe forms in 21.4%. The severity was associated with allergic comorbidities such as asthma (p = 0.001) and allergic conjunctivitis (p <0.001). Severe AD was associated with a state of anxiety and depression (p <0.05), as well as with ocular affectation (p<0.001).\u0000\u0000\u0000CONCLUSION\u0000The pediatric population is the most affected by AD; however, in the adult population, the severe form associated with allergic comorbidities is observed.","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 1","pages":"12-25"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39250125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Argentine Consensus of the Diagnosis and Treatment of Hereditary Angioedema].","authors":"Daniel O Vazquez,&nbsp;Darío O Josviack,&nbsp;Claudio A Fantini,&nbsp;Natalia L Fili,&nbsp;Alejandro M Berardi,&nbsp;Ricardo D Zwiener,&nbsp;René A Baillieau,&nbsp;Gonzalo F Chorzepa,&nbsp;Gabriel O Fueyo,&nbsp;Claudia M García,&nbsp;Gabriel Gattolin,&nbsp;Mónica B Marocco,&nbsp;Claudio A S Parisi,&nbsp;Marcelo D Strass,&nbsp;José E Fabiani","doi":"10.29262/ram.v68i6.914","DOIUrl":"https://doi.org/10.29262/ram.v68i6.914","url":null,"abstract":"<p><strong>Objectives: </strong>Hereditary angioedema (HAE) is a rare disease. During the last years, many studies and advances have been developed with the aim of better understanding the pathophysiology, as well as optimizing patient management. Several international working groups have attempted to clarify and standardize the care of HAE communicated as guidelines and consensus recommendations. We considered necessary to provide recommendations for the diagnosis and treatment of patients with HAE in Argentina.</p><p><strong>Methods: </strong>A group of specialists of allergy and immunology from Argentina by using the online surveys methodology as well as face to face meetings developed the intended consensus.</p><p><strong>Results: </strong>Recommendations were established based on published evidence and the expert opinion. The consensus focused on diagnosis, acute management of attacks, short and long-term prophylaxis, special situations (pediatrics and pregnancy) and disease management considering the health care system in Argentina.</p><p><strong>Conclusion: </strong>The recommendations established in this consensus guidelines will optimize the management of patients with HAE in Argentina.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"68 Suppl 2 ","pages":"s1-s22"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39304383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}